title: Modulation of postoperative scarring with tacrolimus and octreotide in experimental glaucoma filtration surgery.
abstract: OBJECTIVE
  The purposes of this study were to investigate the effects of topically administrated Tacrolimus and Octreotide on modulation of postoperative scarring in experimental glaucoma filtration surgery and to compare the antifibrotic properties of these agents with mitomycin-C (MMC).
  
  
  METHODS
  A total of 28 New Zealand rabbits weighing 2.5-3 kg were randomly divided into a surgical control (SC) group and three experimental groups. Standard filtration surgeries were performed on the right eyes of all the rabbits. The rabbits in the SC group received only vehicle after the surgeries, whereas the rabbits in the three experimental groups were treated either with 0.4 mg/mL MMC during the surgery (MMC group) or with 0.3 mg/mL Tacrolimus drop four times a day (TT group) or with 10 µg/mL Octreotide drop three times a day (OT group) for 14 days. The animals were killed on day 14, eyes were enucleated and histologically and immunohistochemically analyzed.
  
  
  RESULTS
  In SC group mean fibroblast, mononuclear cell number and fibroblast growth factor-β (FGF-β), transforming growth factor-β (TGF-β) immunostaining intensity was higher than all treatment groups. In OT group mean fibroblast number was lesser than MMC (p < 0.01) and TT (p < 0.05) group. In TT group mean fibroblast number was lesser than MMC group (p < 0.05). Mean mononuclear cell number was similar between MMC, OT and TT groups (p > 0.05). In MMC, OT and TT groups mean TGF-β and FGF-β immunostaining intensity was similar (p > 0.05).
  
  
  CONCLUSIONS
  Topically administration of Tacrolimus and Octreotide effectively reduced the subconjuntival scarring response 2 weeks after experimental glaucoma filtration surgery.
authors.affiliation: Department of Ophthalmology, School of Medicine, Fırat University, Elazig, Turkey.
authors.forename: Sermal
authors.initials: S
authors.lastname: Arslan
authors.forename: Orhan
authors.initials: O
authors.lastname: Aydemir
authors.forename: Mete
authors.initials: M
authors.lastname: Güler
authors.forename: Adile Ferda
authors.initials: AF
authors.lastname: Dağlı
mesh_terms: D000287:Administration, Topical; D000477:Alkylating Agents / Q000008:administration & dosage; D000818:Animals; D002921:Cicatrix / Q000378:metabolism / Q000517:prevention & control*; D003229:Conjunctival Diseases / Q000378:metabolism / Q000517:prevention & control*; D004195:Disease Models, Animal; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D005347:Fibroblasts / Q000473:pathology; D005355:Fibrosis / Q000517:prevention & control; D018463:Filtering Surgery; D005901:Glaucoma / Q000378:metabolism / Q000601:surgery*; D007124:Immunoenzyme Techniques; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007958:Leukocyte Count; D016685:Mitomycin / Q000008:administration & dosage; D015282:Octreotide / Q000008:administration & dosage*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D011183:Postoperative Complications; D011817:Rabbits; D016559:Tacrolimus / Q000008:administration & dosage*; D016212:Transforming Growth Factor beta / Q000378:metabolism
chemical_list: D000477:Alkylating Agents; D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D016212:Transforming Growth Factor beta; D016222:Fibroblast Growth Factor 2; D016685:Mitomycin; D015282:Octreotide; D016559:Tacrolimus